COCHAIRS:
Thomas F. Gajewski, University of Chicago, Chicago, IL
Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX
Jedd D. Wolchok, Weill Cornell Medicine, New York, NY

[ R ] – remote presentation

FRIDAY, OCTOBER 21

Registration
3:00 pm-8:00 pm | Grand Liberty Foyer

Welcome and Opening Keynote Lecture
6:30 pm-7:30 pm | Grand Liberty Ballroom
6:30-6:35 Welcome and Introduction of Keynote Speaker
Thomas F. Gajewski, University of Chicago, Chicago, IL
6:35-7:15 Stromal evolution in inflammation and cancer
Shannon J. Turley, Genentech, South San Francisco, CA
7:15-7:30 Discussion / Q&A

Opening Reception
7:30 pm-9:30 pm | Back Bay Ballroom

SATURDAY, OCTOBER 22

Breakfast
7:00 am-8:00 am | Grand Liberty Foyer

Plenary Session 1: Adoptive T Cell Therapy with a Focus on Challenges in Solid Tumors
8:00 am-9:25 am | Grand Liberty Ballroom
Session Chair: Thomas F. Gajewski, University of Chicago, Chicago, IL

8:00-8:25 Engineering CAR T cells for enhanced efficacy and specificity
Robbie Majzner, Stanford University School Medicine, Stanford, CA
8:25-8:35 Discussion / Q&A
8:35-9:00 TCR-gene therapy targeting mutant KRAS
Eric Tran, Providence Cancer Institute, Portland, OR
9:00-9:10 Discussion / Q&A
9:10-9:25 Panel Discussion
Break
9:25 am-9:45 am | Grand Liberty Foyer

Plenary Session 2: Next-Generation Checkpoints Beyond PD-1 and CTLA-4
9:45 am-11:45 am | Grand Liberty Ballroom
Session Chair: Roberta Zappasodi, Weill Cornell Medicine, New York, NY

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45-10:10</td>
<td>Targeting the LAG-3 immune checkpoint in cancer</td>
<td>Evan J. Lipson</td>
<td>Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD</td>
</tr>
<tr>
<td>10:10-10:20</td>
<td>Discussion / Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20-10:45</td>
<td>Targeting the adenosine pathway to augment the immune response</td>
<td>Zev A. Wainberg</td>
<td>UCLA Medical Center, Santa Monica, CA</td>
</tr>
<tr>
<td>10:45-10:55</td>
<td>Discussion / Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:55-11:20</td>
<td>Modulating tumor metabolism to reprogram the immune microenvironment against cancer</td>
<td>Roberta Zappasodi</td>
<td></td>
</tr>
<tr>
<td>11:20-11:30</td>
<td>Discussion / Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Lunch on Own / Free Time
11:45 am-1:45 pm

Plenary Session 3: Spatial Analysis of the Tumor Microenvironment
1:45 pm-3:45 pm | Grand Liberty Ballroom
Session Chair: Roberta Zappasodi, Weill Cornell Medicine, New York, NY

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:45-2:10</td>
<td>The power of ONE: Immunology in the age of single cell genomics</td>
<td>Ido Amit</td>
<td>Weizmann Institute of Science, Rehovot, Israel</td>
</tr>
<tr>
<td>2:10-2:20</td>
<td>Discussion / Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:20-2:45</td>
<td>[ R ] - Cancer rearranges the rules in tissue building blocks. A new class of targets for therapy?</td>
<td>Garry P. Nolan</td>
<td>Stanford University School of Medicine, Stanford, CA</td>
</tr>
<tr>
<td>2:45-2:55</td>
<td>Discussion / Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:55-3:20</td>
<td>Integrating multi-omics to unlock insights into cancer immunotherapy against hepatocellular carcinoma</td>
<td>Won Jin Ho</td>
<td>Johns Hopkins University, Baltimore, MD</td>
</tr>
<tr>
<td>3:20-3:30</td>
<td>Discussion / Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
3:30-3:45  Panel Discussion

**Poster Session A / Reception**
4:00 pm-6:30 pm | Back Bay Ballroom

---

**SUNDAY, OCTOBER 23**

**Breakfast**
7:00 am-8:00 am | Grand Liberty Foyer

**Plenary Session 4: Computational Models/AI/Big Data**
8:00 am-10:00 am | Grand Liberty Ballroom  
*Session Chair: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX*

- 8:00-8:25  Systems biology modeling of tumor immunotherapy  
  Lance L. Munn, Massachusetts General Hospital, Charlestown, MA

- 8:25-8:35  Discussion / Q&A

- 8:35-9:00  Immune selection and predictability of cancer evolution  
  Marta Luksza, Icahn School of Medicine at Mount Sinai, New York, NY

- 9:00-9:10  Discussion / Q&A

- 9:10-9:35  What about cancer is “not self”?  
  Benjamin D. Greenbaum, Memorial Sloan Kettering Cancer Center, New York, NY

- 9:35-9:45  Discussion / Q&A

- 9:45-10:00  Panel Discussion

**Break**
10:00 am-10:20 am | Grand Liberty Foyer

**Plenary Session 5: Host Factors Regulating Efficacy and Resistance**
10:20 am-12:20 pm | Grand Liberty Ballroom  
*Session Chair: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX*

- 10:20-10:45  Insights from translational research on response to cancer therapy  
  Jennifer A. Wargo

- 10:45-10:55  Discussion / Q&A

- 10:55-11:20  Elucidating the impact of the microbiome on CAR T cell therapy  
  Melody Smith, Stanford University, Stanford, CA

- 11:20-11:30  Discussion / Q&A
11:30-11:55  An unexpected role for androgens in limiting cancer immunotherapy efficacy  
Amy Moran, Oregon Health & Science University, Portland, OR  
11:55-12:05  Discussion / Q&A  
12:05-12:20  Panel Discussion  

Lunch on Own / Free Time  
12:20 pm-2:30 pm  

Plenary Session 6: Myeloid Cells in the Tumor Microenvironment  
2:30 pm-3:40 pm | Grand Liberty Ballroom  
Session Chair: Thomas F. Gajewski, University of Chicago, Chicago, IL  
2:30-2:55  The complexities of tumor associated macrophages and the key to effective targeting for anti-cancer therapy  
Jennifer L. Guerriero, Dana-Farber Cancer Institute, Boston, MA  
2:55-3:05  Discussion / Q&A  
3:05-3:30  Commensal microbiota and germline variants can regulate anti-tumor immunity through myeloid cells  
Thomas F. Gajewski  
3:30-3:40  Discussion / Q&A  

Keynote Lecture  
3:40 pm-4:40 pm | Grand Liberty Ballroom  
3:40-3:45  Introduction of Keynote Speaker  
Amy Moran, Oregon Health & Science University, Portland, OR  
3:45-4:25  Sex bias and cancer immunotherapy: Time has come  
Zihai Li, The Ohio State University – Pelotonia Institute for Immuno-Oncology, Columbus, OH  
4:25-4:40  Discussion / Q&A  

Poster Session B / Reception  
5:00 pm-7:30 pm | Back Bay Ballroom  

MONDAY, OCTOBER 24  

Breakfast  
7:00 am-8:00 am | Grand Liberty Foyer
Plenary Session 7: Mechanisms of IO Toxicity
8:00 am-10:00 am | Grand Liberty Ballroom
Session Chair: Ryan J. Sullivan, Massachusetts General Hospital, Boston, MA

8:00-8:25 Checkpoint blockade–induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1/Tc1 cytokines
Robin Reschke, University of Chicago, Chicago, IL
8:25-8:35 Discussion / Q&A

8:35-9:00 ICI-associated myocarditis: Bench to bedside
Javid Moslehi, University of California, San Francisco, CA
9:00-9:10 Discussion / Q&A

9:10-9:35 Uncoupling anti-tumor immunity and auto-inflammatory toxicity from immune checkpoint inhibition
Ryan J. Sullivan
9:35-9:45 Discussion / Q&A

9:45-10:00 Panel Discussion

Break
10:00 am-10:20 am | Grand Liberty Foyer

Plenary Session 8: Neoadjuvant IO
10:20 am-12:20 pm | Grand Liberty Ballroom
Session Chair: Matthew Galsky, Icahn School of Medicine at Mount Sinai, New York, NY

10:20-10:45 Personalization of neoadjuvant therapy in melanoma: A template for other tumors?
Christian Blank, Netherlands Cancer Institute, Amsterdam, Netherlands
10:45-10:55 Discussion / Q&A

10:55-11:20 The evolution of neoadjuvant immunotherapy in bladder cancer
Matthew Galsky, Icahn School of Medicine at Mount Sinai, New York, NY
11:20-11:30 Discussion / Q&A

11:30-11:55 [ R ] - From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX
11:55-12:05 Discussion / Q&A

12:05-12:20 Panel Discussion
Departure
12:20 pm